NDAORALTABLETPriority Review
Approved
Oct 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
3/8 — Basic
Priority Review
LONITEN (minoxidil) by Pfizer is clinical pharmacology 1. First approved in 1979.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LONITEN (minoxidil) is an oral direct-acting peripheral vasodilator approved in 1979 for severe hypertension resistant to other therapies. It reduces blood pressure by decreasing peripheral vascular resistance and enhancing microcirculatory blood flow. The drug is typically used in combination with a diuretic and beta-blocker to manage severe hypertension and its associated complications like encephalopathy and retinopathy.
LOE Approaching
Product approaching loss of exclusivity with minimal linked job opportunities; limited career growth potential on this aging brand.
Mechanism of Action
CLINICAL PHARMACOLOGY 1. General Pharmacologic Properties Minoxidil is an orally effective direct acting peripheral vasodilator that reduces elevated systolic and diastolic blood pressure by decreasing peripheral vascular resistance. Microcirculatory blood flow in animals is enhanced or maintained…
Worked on LONITEN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.